个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon? [作者：Macchiarulo, A; Giacche, N; Mancini, F; Puxeddu, E; Moretti, F; Pellicciari, R,期刊：Expert Opinion on Therapeutic Patents, 页码：287-294 , 文章类型： Editorial Material，,卷期：2011年21-3] Most researchers have sought to restore the activity of p53 by identifying small molecules able to block the interaction of p53 with mouse double minute 2 (MDM2). To the same end, some scientists are pursuing the develop... Advances in human papilloma virus vaccines: a patent review [作者：Cho, HJ; Oh, YK; Kim, YB,期刊：Expert Opinion on Therapeutic Patents, 页码：295-309 , 文章类型： Review，,卷期：2011年21-3] Introduction: Human papilloma virus (HPV) infection is the main factor associated with the development of cervical cancer. The currently available HPV vaccines, Gardasil (R) and Cervarix (R), can prevent infection by cer... Cathepsin S inhibitors: 2004-2010 [作者：Lee-Dutra, A; Wiener, DK; Sun, SQ,期刊：Expert Opinion on Therapeutic Patents, 页码：311-337 , 文章类型： Review，,卷期：2011年21-3] Introduction: Cathepsin S, a lysosomal cysteine protease, plays an important role in antigen presentation. Its inhibition is expected to result in immunosuppression, making this enzyme an attractive target to potentially... Neutrophil elastase inhibitors [作者：Groutas, WC; Dou, DF; Alliston, KR,期刊：Expert Opinion on Therapeutic Patents, 页码：339-354 , 文章类型： Review，,卷期：2011年21-3] Introduction: Chronic obstructive pulmonary disease (COPD) constitutes a worldwide health problem. There is currently an urgent and unmet need for the development of small molecule therapeutics capable of blocking and/or... Novel adenosine 5 '-triphosphate-sensitive potassium channel ligands: a patent overview (2005-2010) [作者：Rapposelli, S,期刊：Expert Opinion on Therapeutic Patents, 页码：355-379 , 文章类型： Review，,卷期：2011年21-3] Introduction: ATP-sensitive potassium channels are important metabolic regulators that link cellular metabolism to excitability. Their wide distribution in various tissues and organs makes them significant and topical ta... Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010) [作者：Calugi, C; Trabocchi, A; Guarna, A,期刊：Expert Opinion on Therapeutic Patents, 页码：381-397 , 文章类型： Review，,卷期：2011年21-3] Introduction: The fungal pathogen Candida albicans is one of the leading causes of infections affecting immunodeficient individuals, including those HIV-infected and patients undergoing cancer therapy. Emerging problems ... Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010 [作者：Singh, IP; Chauthe, SK,期刊：Expert Opinion on Therapeutic Patents, 页码：399-416 , 文章类型： Review，,卷期：2011年21-3] Introduction: The first US FDA approved HIV entry inhibitor drug Enfuvirdine belongs to the fusion inhibitor category. Earlier efforts in this area were focused on peptides and monoclonal antibodies; recently, the focus ... New H1/H3 antagonists for treating allergic rhinitis: WO2010094643 [作者：Norman, P,期刊：Expert Opinion on Therapeutic Patents, 页码：424-429 , 文章类型： Article，,卷期：2011年21-3] This application claims dual receptor specificity antihistamines, active as H-1 and H-3 antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalati... Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1 [作者：Wu, JH; Zhao, M; Peng, SQ,期刊：Expert Opinion on Therapeutic Patents, 页码：431-435 , 文章类型： Article，,卷期：2011年21-3] An application claims non-naturally occurring upregulators of apolipoprotein A-1 (ApoA-1) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-1, and...